Meera Mahalingam, MBBS, PhD, FRCPath


Professor of Dermatology, Pathology

and Laboratory Medicine

Program Director, Dermatopathology Fellowship Training


Administrative Office:

Boston University School of Medicine, Dept of Dermatology

609 Albany Street, Boston, MA 02118

Tel: 617-638-5500  Fax 617-638-5515


  • Received her medical degree in India (MBBS)
  • Trained in pathology initially in the UK and subsequently in the USA
  • Obtained a PhD from the University of London while doing her residency in pathology


She is a board certified pathologist (UK and USA) and a board certified dermatopathologist. Subsequent to completion of the dermatopathology fellowship from BUSM, she joined Quest Diagnostics Inc., Cambridge as consultant dermatopathologist. Meera was recruited to UMass Medical School Center as Associate professor of Pathology and Medicine, Director of Dermatopathology and Program Director of the Dermatopathology Fellowship training Program in 2005 and, to BUSM as Associate professor of Dermatology and Pathology in 2007.  Meera was promoted to professor of Dermatology, Pathology and Laboratory Medicine in 2009 and is the Program Director of the Dermatopathology Fellowship training at Boston University School of Medicine, Boston, MA (Fellowship Information Page).  She has served on the Board of the American Society of Dermatopathology since 2003 as Director of Quality Assurance and Laboratory Proficiency (2003-07) and pioneered the digital quality assurance program. Editorial boards she serves on include Journal of Cutaneous Pathology (official journal of the American Society of Dermatopathology) where she initiated the journal CME program in 2007 and Modern Pathology (official journal of the United States and Canadian Academy of Pathology). Meera has over a 100 publications in reputed scientific journals such as Cell, Modern Pathology, British Journal of Dermatology, Human Pathology and Histopathology.  Her special interests include cutaneous lymphoproliferative disease and on improving diagnostic accuracy of various skin tumors with particular emphasis on atypical pigmented lesions by examining the morphologic features of lesions by light microscopy and utilizing techniques that include the genomic analyses of select mutations affecting the MAP kinase pathway (known to be commonly affected in melanocytic neoplasias) to explore their potential as ancillary methods for diagnosis or prognosis.

Selected Publications

1. Mahalingam M, Nguyen LP, Richards JE, Muzikansky A, Hoang MP. The Diagnostic Utility of Immunohistochemistry in Distinguishing Primary Skin Adnexal Carcinomas from Metastatic Adenocarcinoma to Skin: an Immunohistochemical Reappraisal Using Cytokeratin 15, Nestin, p63, D2-40, and Calretinin. Mod Pathol, 2010; 23(5): 713

2. DeCarlo K, Yang S, Emley A, Wajapeyee N, Green M, Mahalingam M. Oncogenic BRAF positive dysplastic nevi and the tumor suppressor IGFBP7– challenging the concept of dysplastic nevi as precursor lesions? Hum Pathol, 2010; 41(6):886

3. Hoang MP, Keady M, Mahalingam M. Stem cell markers (cytokeratin 15, CD34 and nestin) in primary scarring and non-scarring alopecia. Br J Dermatol 2009; 160:609

4. Dadzie O, Yang S, Emley A, Keady M, Bhawan J, Mahalingam M. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma – clues to melanomagenesis. Br J Dermatol 2009; 160:368

5. Wajapayee N, Serra R, Zhu X, Mahalingam M, Green MR. Oncogenic BRAF induces senescence through an autocrine/paracrine pathway mediated by the secreted protein IGFBP7. Cell 2008; 132:363